
Neuland Laboratories Ltd
NSE:NEULANDLAB

Neuland Laboratories Ltd
Net Income (Common)
Neuland Laboratories Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Neuland Laboratories Ltd
NSE:NEULANDLAB
|
Net Income (Common)
â‚ą3B
|
CAGR 3-Years
72%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
![]() |
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
â‚ą53.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
![]() |
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
â‚ą49.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
25%
|
CAGR 10-Years
15%
|
|
![]() |
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
â‚ą114.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
8%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
â‚ą18.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Income (Common)
â‚ą19.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Neuland Laboratories Ltd
Glance View
Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.

See Also
What is Neuland Laboratories Ltd's Net Income (Common)?
Net Income (Common)
3B
INR
Based on the financial report for Dec 31, 2024, Neuland Laboratories Ltd's Net Income (Common) amounts to 3B INR.
What is Neuland Laboratories Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
56%
Over the last year, the Net Income (Common) growth was -5%. The average annual Net Income (Common) growth rates for Neuland Laboratories Ltd have been 72% over the past three years , 56% over the past five years .